ARTV Artiva Biotherapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ARTV matters now
Artiva Biotherapeutics, Inc. (ARTV) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.64 with +2.44% on the session and $238.3M in market capitalization; recent performance reads 1-month +14.85% and YTD +128.90%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.5M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -33.0%.
The latest indexable market news headline is "Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $37.50; recent insider activity includes RA CAPITAL MANAGEMENT, L.P. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.76
P/S
0.00
EV/EBITDA
-2.75
DCF Value
$0.66
FCF Yield
-33.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-82.2%
ROIC
-93.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.5M | $-0.95 |
| Q4 2025 | $0.00 | $-20.8M | $-0.85 |
| FY 2025 | $0.00 | $-83.9M | $-3.43 |
| Q3 2025 | $0.00 | $-21.5M | $-0.88 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$37.50
Target (Median)
$37.50
Target Range
$35.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.40
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.